facilitate the detection of subtle effects [6] .
Additionally, adult participants in nutrition studies who are cognitively unimpaired fall within a range in several demographic features that likely have an impact on the efficacy of the nutrient intervention used. For example, race was directly associated with cognitive functioning and indirectly associated through social risk factors such as education and health insurance [7] , thereby influencing the outcome of cognitive testing, it is therefore necessary for study design to be cognizant of these variables.
Inclusion/exclusion criteria must allow for screening of individuals presenting a genetic risk of cognitive decline, identified through polymorphisms in Brain-Derived Neurotrophic Factor (BDNF), Catechol-O-methyltransferase (COMT) and Apolipoprotein (APOE) genes [8] , or contrariwise presenting a genetic advantage in cognition tests, identified through increased levels of the Klotho gene variant [9] .
Inconsistencies in results obtained using MMSE as a tool to detect meaningful differences in cognitive function in nutrition studies have participants with elevated homocysteine levels [10] . In contrast, elderly individuals suffering from chronic fatigue syndrome showed a significant improvement in MMSE score after supplementation with acetyl L-carnitine compared to a placebo (3.4 vs. 0.5 respectively) [11] . Corroborating the aforementioned finding are the results of a longitudinal study of healthy individuals where the cognitive state of a crosssectional sample was analyzed in response to consumption of fruits and vegetables.
Here, the MMSE used as a measure of global cognitive function uncovered an effect of diet on cognition [12] .
Randomized Controlled Trials in Clinical Nutrition
The gold standard for scientific evidence is the randomized controlled trial (RCT), which has been unequivocally accepted in order to make valid health claims in the nutraceutical and pharmaceutical industries. However, the design of a clinical trial should be subject to the product being tested. Pharmaceutical drugs [32], indicating that while CDRCAB has been widely used in drug trials, aspects of this tool can be adapted to the nutraceutical industry.
The Computerized Mental Performance
Assessment System (COMPASS) has been used in several nutritional intervention studies [33] [34] [35] and was found to be sensitive to cognitive enhancement following supplementation [36] . For example, in a study on healthy males, a high dose vitamin B complex with mineral supplement showed a significant enhancement in the COMPASS Serial 3s subtraction task, an attention domain in cognition, and also boosted mental energy among participants [37] . A pilot study likewise showed improvement in working memory that was evaluated using COMPASS [38] .
As mentioned earlier, MMSE suffers from an inability to detect subtle changes in cognition.
In fact, at 90% sensitivity for discriminating patients with mild cognitive impairment from healthy controls, the specificity ranged between 65 -85%. Again, when discriminating between patients with dementia from healthy controls, at a sensitivity of 90%, the specificity ranged between 50 and 81%. Therefore, as most cognition testing tools lack the predictive power to discriminate between those with mild impairment and those with more advanced cognitive decline, it is not surprising that if artificially set at 90% sensitivity, the specificity to discriminate between improved cognition with dietary supplements in an healthy population may be predicted to be poor as well. 
A Global Index for Cognitive Health
Global In the case of neurological health, particularly cognitive improvement through nutrition, identifying a global index for cognitive health that reflects health rather than disease and is tailored to the unique features of nutrients actions and interactions may help overcome the design problems that have resulted in a growing number of failed trials of individual nutrients [44] . A global index may be a primary endpoint for studies to determine the effect of nutrients on cognition. For example, there is good evidence that suggests vitamin E plays a role in treating cognitive decline or dementia. In a large prospective cohort study comprising 5395 participants (> 55 years) who were followed for over 9.6 years, high intake of vitamin E-rich foods was found to modestly reduce development of dementia by 25% compared to those with the lowest intake of vitamin E [45] . Vitamin E has an effect as an antioxidant playing a key role in protecting membranes from oxidation, peroxidation of docosahexaenoic acid in the brain, and reducing the risk of mild cognitive impairment by 15% in people with the highest levels of tocopherols and by 8% in the case of tocotrienols [46] . Vitamin E, in addition to being an antioxidant, is also involved in immune The rationale for a global index encompassing multiple endpoints that incorporates physiological, immunological and biochemical markers is a systems biology approach to studying outcomes. This is particularly evident in the case of cognitive functions that should not be thought of solely in terms of the nervous system, but also that environmentally linked changes in brain architecture continue throughout the lifespan, due to the plasticity of the brain [47] . An important environmental variable to consider in relation to brain function is, as was previously mentioned, nutrition [47] .
Nutrition is known to be a relevant effector of health and disease [48] , with contributions from the immune [49] and vascular systems [50] .
Pooling and measuring biomarkers of 
